SAINT FRANCIS HOSPITAL/NATALIE WARREN BRYANT CCOP

娜塔莉·沃伦·布莱恩特癌症中心(NWBCC)是目前由 社区临床肿瘤学计划(CCOP)是一种物理和 俄克拉何马州塔尔萨圣弗朗西斯医院的行政部门。 圣弗朗西斯医院是一家拥有750个床位的非营利性教学医院，为 俄克拉荷马州东北部和堪萨斯州部分地区的160万居民， 密苏里州和阿肯色州。NWBCC是中国最大的癌症护理机构 该地区每年登记约1500名新的癌症患者。 该项目与ECOG建立了13年的合作关系， 平均每年患者收益为90-100人。由于CCOP的资助， 还与M.D.安德森和NSABP建立了联系。 NWBCC CCOP现在正在申请继续作为双组件计划 由NWBCC/Saint Francis和癌症护理协会组成，靠近 医院校园。癌症护理协会是核心调查人员 负责过去11年的癌症项目开发。二 NWBCC ECOG附属机构、Hillcrest医疗中心和塔尔萨地区医疗 中心(前俄克拉荷马州骨科医院)已经增加，带来了 NWBCC-CCOP真正在全市参与NCI批准的临床 预期可为172名患者带来收益的试验和癌症控制项目 治疗方案和557项癌症控制研究。分析 患者记录显示，NWBCC-CCOP将40%的合格新患者 NCI批准的试验的患者，除了我们自己的内部收益外 调查。

The Natalie Warren Bryant Cancer Center (NWBCC) is a currently funded Community Clinical Oncology Program (CCOP) which is a physical and administrative component of Saint Francis Hospital in Tulsa, Oklahoma. Saint Francis Hospital is a 750 bed non-profit teaching hospital serving the 1.6 million residents of Northeastern Oklahoma and portions of Kansas, Missouri, and Arkansas. The NWBCC is the largest provider of cancer care in the area and registers approximately 1,500 new cancer patients annually. The program has enjoyed a thirteen year relationship with ECOG with an average patient accrual of 90-100 per year. As a result of CCOP funding, affiliations have also been established with M.D. Anderson and NSABP. The NWBCC CCOP is now applying for continuation as a dual component program consisting of NWBCC/Saint Francis and Cancer Care Associates, near the hospital campus. Cancer Care Associates are the core investigators responsible for cancer program development for the past eleven years. Two NWBCC ECOG affiliates, Hillcrest Medical Center and Tulsa Regional Medical Center (formerly Oklahoma Osteopathic Hospital) have been added, bringing to the NWBCC-CCOP true city-wide participation in NCI-approved clinical trials and cancer control projects with anticipated accrual of 172 patients to the treatment protocols and 557 to cancer control studies. Analysis of patient logs has shown that the NWBCC-CCOP places 40% of eligible new patients on NCI-approved trials, in addition to accrual to our own in-house investigations.